BackKyverna Therapeutics Overview

Kyverna Therapeutics Other Current Liabilities

Latest other current liabilities for KYTX: $18M.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$18.34M
30.24% YoYΔ $-7.95M vs prior year quarter

Peer trimmed avg / median

Loading

Kyverna Therapeutics Other Current Liabilities History

Loading

Kyverna Therapeutics vs. peers: Other Current Liabilities Comparison

Loading

Kyverna Therapeutics Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Kyverna Therapeutics (KYTX) FAQ

As of the most recent data (June 2026), KYTX shows a other current liabilities of $18M. That compares with $26M in the prior-year period — down 30.2% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, KYTX's other current liabilities is now $18M (was $26M) — a 30.2% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Kyverna Therapeutics is outperforming or lagging.

Tracking KYTX's other current liabilities over time shows whether Kyverna Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $18M That compares with $26M in the prior-year period — down 30.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other current liabilities page, Stockcircle has Kyverna Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current liabilities (currently $18M) with ownership activity and broader fundamentals.